Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction
Published version of a preprint
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Abstract Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of this resistance remain elusive. Using a genome-wide loss-of-function screen, we identified that impaired death receptor signaling in ALL led to rapidly progressive disease despite CART19 treatment. This was mediated by an inherent resistance to T-cell cytotoxicity that permitted antigen persistence and was subsequently magnified by the induction of CAR T-cell functional impairment. These findings were validated using samples from two CAR T-cell clinical trials in ALL, where we found that reduced expression of death receptor genes was associated with worse overall survival and reduced T-cell fitness. Our findings suggest that inherent dysregulation of death receptor signaling in ALL directly leads to CAR T-cell failure by impairing T-cell cytotoxicity and promoting progressive CAR T-cell dysfunction. Significance: Resistance to CART19 is a significant barrier to efficacy in the treatment of B-cell malignancies. This work demonstrates that impaired death receptor signaling in tumor cells causes failed CART19 cytotoxicity and drives CART19 dysfunction, identifying a novel mechanism of antigen-independent resistance to CAR therapy. See related commentary by Green and Neelapu, p. 492.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, CRISPR screening showed that loss of tumor-associated death receptors leads to CAR T-cell resistance.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [30]
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096 · cited 1×
“Downstream analysis and visualization was done using HOMER (44) and deepTools2 (45).”
MethodBuenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422 · cited 2×
“Purification of transposed DNA was completed with DNA Clean and Concentrator (Zymo), and fragments were barcoded with ATAC-seq indices (39).”
BackgroundMethodTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · cited 2×
“Death Receptor Gene Expression Correlates with Clinical Outcomes after CAR T-cell Therapy in ALL In light of these preclinical observations, we investigated the association between leukemia expression of death receptor genes and clinical outcomes after treatment with tisagenlecleucel, a CD19 CAR T-cell clinical produc…”
MethodSelf-citation
Cited by
Items 201–295 of 295
Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
Aydilek, E., Klein‐Scory, S., Thomson, J., Nilius‐Eliliwi, V., Vangala, D., Schroers, R., Wulf, G. G., & Mika, T. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000949 · Cited by 7
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies
Carturan, A., Angelos, M. G., Guruprasad, P., Patel, R. P., Pajarillo, R., Lee, A. E., Zhang, Y., Zhang, Y., Xie, W., Rodriguez, J. L., et al. (2026) · Blood · doi:10.1182/blood.2025031409 · Cited by 6
New CARs on and off the road: challenges and new developments in CAR-T cell therapy
Wehrli, M., & Maus, M. V. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.05.005 · Cited by 5
CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacy
Zaki, A. A., McCurry, D., & Strati, P. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2185090 · Cited by 5
“Novel therapeutic strategies, such as the integration of anti-CD47 and/or anti-SIRPa antibodies, into bridging and conditioning regimens, may result in better CAR T-cell amplification and improved function [56,57].”
BackgroundThe costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignanciesPreprint
Krawczyk, M., Fernández‐Fuentes, N., Fidyt, K., Winiarski, T., Pępek, M., Graczyk‐Jarzynka, A., Davis, J., Bousquets‐Muñoz, P., Puente, X. S., Menéndez, P. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.28.640707 · Cited by 7
“The advantage of our models above other resistant models produced so far with CRISPR/Cas9 library [69–71] or with artificial expression of CD19 [45] is that we generated resistant cells upon CAR-T cells pressure that can reflect natural physiology and clinical experience.”
Yan, D., Yi, W., Wu, T., Hu, S., Ding, Y., Qian, X., Zhao, Z., Wang, D., Xu, H., Cai, Y., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114324 · Cited by 5
Menéndez, J. A., Lupu, R., Martín-Castillo, B., Sardanyés, J., Alarcón, T., Verdura, S., & Cuyàs, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1695244 · Cited by 7
A Comprehensive Review on Unravelling the Complexity of Blood Cancer
Saha, S., Ghosh, S., Ghosh, S., & Nandi, S. (2024) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2024.v84i03.020 · Cited by 10
The road ahead for chimeric antigen receptor T cells
Stewart, C. M., Siegler, E. L., & Kenderian, S. S. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf047 · Cited by 4
Soliman, N., Nedelko, T., Mandracci, G., Enßle, S., Grass, V., Fischer, J. C., Bassermann, F. C., Poeck, H., Kobold, S., Khawanky, N. E., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3425 · Cited by 5
“…apoptotic cell death has been shown to be independent of FADD and caspase-8 activity in tumor cells (7) and may therefore overcome tumor cell resistance to CAR T cells due to the previously proposed mechanism of impaired death receptor signaling following loss of the genes FADD and/or CASP8 (3) .”
InfluentialShao, L., Iyer, A., Zhao, Y., Somerville, R. P., Panch, S. R., Pelayo, A., Stroncek, D. F., & Jin, P. (2022) · Scientific Reports · doi:10.1038/s41598-022-06830-3 · Cited by 5
Lewis glycosphingolipids as critical determinants of TRAIL sensitivity in cancer cells
Fukuoka, T., Moriwaki, K., Takamatsu, S., Kondo, J., Tanaka, M., Tomioka, A., Semba, M., Komazawa‐Sakon, S., Kamada, Y., Kaji, H., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02434-3 · Cited by 5
“In addition, recent studies involving the use of unbiassed genome-wide CRISPR/Cas9 screening revealed that TRAIL resistance is a vital intrinsic mechanism that renders cancer cells insensitive to chimeirc antigen receptor (CAR)T therapy [37, 38].”
BackgroundLam, C. K. (2023) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2023.09.008 · Cited by 4
Ligon, J. A., Ramakrishna, S., Ceppi, F., Calkoen, F., Diorio, C. J., Davis, K. L., Jacoby, E., Gottschalk, S. M., Schultz, L. M., & Capitini, C. M. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.012 · Cited by 5
Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults
Kimble, E. L., & Cassaday, R. D. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1964022 · Cited by 4
Modified T cells as therapeutic agents
Singh, N. (2021) · Hematology · doi:10.1182/hematology.2021000262 · Cited by 5
Wang, Y., Drum, D. L., Sun, R., Zhang, Y., Yu, L., Jia, L., Isakoff, S. J., Kehlmann, A. M., Dal, A. E., Dotti, G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2595410/v1 · Cited by 4
Lüönd, F., Whalen, J., Song, Y., Schriefer, K., Newcombe, R., Orlando, E. J., Choi, S. M., Ruella, M., Fraietta, J. A., Schuster, S. J., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0176 · Cited by 8
“More recently, in vitro drug screening and/or CRISPR-based loss-of-function screens demonstrated that impaired apoptosis, especially impairment of death receptor signaling pathways, enable cancer cells to autonomously re-sist CAR T cell–mediated cell killing (30–32).”
Ma, X., Zhu, Q., Wu, Z., & Han, W. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090712 · Cited by 8
“To further investigate the association between PSMB9 expression levels and clinical outcomes of CAR-T cell therapy, we evaluated the bulk RNA sequencing data of leukemia-infiltrated bone marrow samples collected prior to CD19 CAR-T therapy from a previously reported study [38].”
Targeting persister cells: proactively overcoming therapy resistance in aggressive B cell lymphomas
Tao, J., Qiu, K., & Williams, M. E. (2026) · Trends in cancer · doi:10.1016/j.trecan.2025.12.007 · Cited by 3
CAR ‐T cell therapy: Advancements in clinical applications and laboratory testing
Nam, M., & Lee, J. (2026) · International Journal of Cancer · doi:10.1002/ijc.70348 · Cited by 3
Caballero, A. C., Escribà-García, L., Pujol‐Fernández, P., Escudero‐López, E., Ujaldón‐Miró, C., Montserrat‐Torres, R., Sierra, J., Álvarez‐Fernández, C., & Briones, J. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00518-6 · Cited by 3
Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma
Munawar, U., Zhou, X., Prommersberger, S., Nerreter, S., Vogt, C., Steinhardt, M., Truger, M. S., Mersi, J., Teufel, E., Han, S., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05683-4 · Cited by 3
“Singh et al. were fi rst to demonstrate the correlation between decreased death receptor expression and primary resistance to CD19 CARTs in ALL 11 .”
BackgroundLeveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness
de Oliveira, B. C., Bari, S. M. N., & Melenhorst, J. J. (2025) · Cancers · doi:10.3390/cancers17030383 · Cited by 5
“Several factors play a role in determining the resistance mechanisms involved with treatment failure, as they can be primary (lack of initial response) or acquired (relapsed response) [23].”
Overcome tumor relapse in CAR T cell therapy
Huo, C., Yang, J., Gu, Y., Wang, D.-J., Zhang, X., & Li, Y. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02847-2 · Cited by 3
“In addition, inherent dysregulation of death receptor signaling also caused the dysfunction of CAR T cells[40].”
BackgroundCytokine-driven cancer immune evasion mechanisms
Arenas, E. J. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2025.01.004 · Cited by 12
Not So FASt: Tumor Cells Resisting Death Drive CAR T-cell Dysfunction
Green, M. R., & Neelapu, S. S. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0037 · Cited by 3
Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy
Qiu, S., Pan, Y., Shi, S., Fapohunda, F. O., Chen, K., Guo, Z., & Lü, P. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.4630 · Cited by 3
“57 In addition, FIG.”
Single-cell functional genomics of natural killer cell evasion in blood cancersPreprint
Dufva, O., Gandolfi, S., Huuhtanen, J., Dashevsky, O., Saeed, K., Klievink, J., Nygren, P. J., Bouhlal, J., Lahtela, J., Näätänen, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.22.504722 · Cited by 3
“…evasion from T cell killing in solid tumors (Kearney et al., 2018; Lawson et al., 2020; Patel et al., 2017) and hematological malignancies (Dufva et al., 2020a; Singh et al., 2020), confirming that unbiased functional genomics can reveal underappreciated aspects of immune-cancer cell interactions.”
BackgroundLan, F., Song, J., Chen, X., & (9093), Y. Z. (2026) · Molecular Immunology · doi:10.1016/j.molimm.2026.02.011 · Cited by 4
Decoding the immune–tumor synapse for data-driven design of next-generation immunotherapies
van Rossum, I., van Spriel, A. B., & van Mierlo, G. (2026) · Trends in Immunology · doi:10.1016/j.it.2025.12.009 · Cited by 3
Arya, R. S., Barrett, D. M., Grupp, S. A., & Melenhorst, J. J. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000513 · Cited by 2
Mechanisms of Resistance and Relapse After CAR-T Cell Therapy
Selli, M. E., Dalal, P., Neelapu, S. S., & Singh, N. (2022) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_12 · Cited by 4
Heterogeneity in functional genetic screens: friend or foe?
Vredevoogd, D. W., & Peeper, D. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162706 · Cited by 3
Ramos, A., Koch, C. E., Liu, Y., Hellinger, R. D., Kyung, T., Abbott, K. L., Fröse, J., Goulet, D. R., Gordon, K. S., Larson, R. C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.15.480217 · Cited by 2
Rasche, L., Duell, J., Leipold, A. M., Appenzeller, S., Fuhr, V., Rauert‐Wunderlich, H., Vià, M. D., Dietrich, O., Toussaint, C., Imdahl, F., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2762036/v1 · Cited by 2
Bachtarzi, H. (2022) · Regenerative Medicine · doi:10.2217/rme-2021-0177 · Cited by 1
Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor
Wang, X., Liu, G., Shi, X., Wang, Y., Jiang, B., Liu, W., Dai, A., Zhang, X., & Yu, F. (2024) · Human Cell · doi:10.1007/s13577-024-01066-x · Cited by 1
“Studies have found that reducing pro-apoptotic factors through exogenous pathways will make B-ALL resistant to CD19·CART killing, leading to clinical drug resistance symptoms [7].”
Liang, X., Guo, J., Wang, X., Luo, B., Fu, R., Chen, H., Yang, Y., Jin, Z., Lin, C., Zang, A., et al. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.10.001 · Cited by 3
Advances in the application of patient-derived xenograft models in acute leukemia resistance
Qin, R., Liang, Y., & Zhou, F. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.18 · Cited by 5
Intrinsic NPRL2 and NPRL3 regulate the sensitivity of B-cell malignancies to CAR-T cell therapy
Han, F., Lu, Y., Zhang, Y., Ma, X., Tong, C., Wei, J., Guo, Y., Liu, C., Wu, Z., Han, W., et al. (2025) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2025.11.007 · Cited by 1
Tang, W., & Yu, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1792910 · Cited by 1
“In this case, continuous antigen exposure not only cannot effectively eliminate the tumor, but also may accelerate CAR-T cell failure (127).”
Chen, X. W., Zhang, J., Chen, H., Huang, R., Zhou, X., Wang, H., Xiao, H., Peng, Q., Wu, F., Zhai, Z., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013255 · Cited by 1
Yang, H., Arita, K., Bowman, K., Chihara, D., Henderson, J. M., Rost, G., Rojas, E., Parsons, S., Lakra, P., Abedin, A. S., et al. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-26-0005 · Cited by 4
Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy
Krawczyk, M., Fidyt, K., Fernández‐Fuentes, N., Winiarski, T., Pępek, M., Bousquets‐Muñoz, P., Puente, X. S., Gutiérrez‐Fernández, A., Davis, J., Owczarek, D., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03081-3 · Cited by 1
The IAP antagonist tolinapant enhances the anti-tumor activity of cell therapies
Tazuru, K., Sone, M., Akamine, H., Kogue, Y., Sims, M., Ward, G. A., Smyth, T., Matsuyama, H., & Sudo, T. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177400 · Cited by 2
Omics analyses provide insights to CART cell therapy resistance
Cox, M. J., & Kenderian, S. S. (2021) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2021.06 · Cited by 1
Yao, S., Yin, X., Chen, T., Chen, W., Zuo, H., Bi, Z., Zhang, X., Jing, Y., Pang, L., & Cheng, H. (2021) · Research Square · doi:10.21203/rs.3.rs-914685/v1 · Cited by 1
Immunotherapy: genetically agnostic in BCP-ALL?
Zwaan, C. M., & Calkoen, F. (2022) · Blood · doi:10.1182/blood.2022015618 · Cited by 1
Editorial: Screening and verification of new targets for CAR-T immunotherapy in cancer
Su, Y., Chen, Y., & Shi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1189773 · Cited by 1
“Genome-wide pooled CRISPR–Cas9 knockout library screening has resulted in the identification of key genes involved in T cell cytotoxicity (10) and genetic alterations in tumor cells that influence resistance to treatment (11).”
BackgroundBrinkmann, B. J., Capraz, T., Roider, T., Knoll, M., Kolb, C., Liu, Y., Angeli‐Terzidou, A., Paramasivam, N., Chapuy, B., Eckstein, V., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.26.546507 · Cited by 2
Reville, P. K., Sheikh, I. N., Choi, A., Dai, E., Henderson, J. M., Li, X., Rojas-Neira, E., Le, C. M. Q., Okwuchi, C., Devonish, M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.28.555127 · Cited by 1
Quantifying target antigen-dependent CAR T-cell performance against AMLPreprint
Shah, S., Mueller, J., Vogel, E., Raatz, M., Boettcher, S., Traulsen, A., Manz, M. G., & Altrock, P. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.16.628628 · Cited by 1
Total body irradiation primes CD19-directed CAR T cells against large B-cell lymphomaPreprint
Alhomoud, M., Foley, M., Sugita, M., Fein, J. A., Yamshon, S., Martinez, L. M., Rejeski, K., Astorkia, M., Betel, D., Brentjens, R. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.17.643462 · Cited by 2
Tumor cell-intrinsic stress states drive sensitivity to CAR T cell-therapy in pancreatic cancerPreprint
Fröse, J., Chen, E., Whittaker, C. A., Leclerc, P., Doherty, S., Langenbucher, A., Shao, J., Hellinger, R. D., Goulet, D. R., Tammela, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.24.666408 · Cited by 1
“Lentiviral supernatant was produced using standard methods.”
RNF19B confers tumor resistance to CAR T cellsPreprint
Geiger, R., Vogel, I. A., Casagranda, A., Cattaneo, M., Morosi, L. G., Pecoraro, M., Sulheim, E., & Basso, C. (2025) · Research Square · doi:10.21203/rs.3.rs-7847831/v1 · Cited by 3
Hays, P. V. (2020) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2020.26.004285
“They have identified that impairments in leukemia and lymphoma death receptor signaling lead to primary CART19 resistance, which in turn mediate progressive CAR T cell functional impairment, revealing a novel mechanism of resistance against CAR T cell therapy.”
MethodInfluentialLee, Y.-H., Lee, H. J., Kim, H. C., Lee, Y., Nam, S. K., Hupperetz, C., Ma, J. S., Wang, X., Singer, O., Kim, W. S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.07.372334
High-Dimensional Immune Monitoring for Chimeric Antigen Receptor T Cell Therapies
Sharma, S. P., Quinn, D. S., Melenhorst, J. J., & Pruteanu-Malinici, I. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00602-4 · Cited by 1
CAR-T-Zellen zur Behandlung von malignen B-Zell-Lymphomen: Ein neues Therapieprinzip
Balke‐Want, H., & Borchmann, P. (2021) · Der Internist · doi:10.1007/s00108-021-01056-3
Potency analysis of cellular therapies: the role of molecular assays
Stroncek, D. F., Jin, P., Shao, L., Wang, E., Ren, J., Castiello, L., Sabatino, M., & Marincola, F. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820493-1.00022-2
The Development and Management of Treatment with Chimeric Antigen Receptor T Cell (CAR T)
Annesley, C., & Gardner, R. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-85147-7_15
Zhang, H., Qin, G., Yang, H., Liu, J., Wu, P., Hu, H., Liu, S., Li, Y., & Zhang, Y. (2020) · Research Square · doi:10.21203/rs.3.rs-117700/v1
Luan, R., & Deng, B. (2023) · Hematology and Oncology Discovery · doi:10.15212/hod-2022-0009
Hagel, K. R., Arafeh, R., Gang, S., Arnoff, T. E., Larson, R. C., Doench, J. G., Mathewson, N. D., Wucherpfennig, K. W., Maus, M. V., & Hahn, W. C. (2023) · doi:10.1158/0008-5472.c.6514376
Lee, Y. G., Guruprasad, P., Ghilardi, G., Pajarillo, R., Sauter, C. T., Patel, R. P., Ballard, H. J., Hong, S. J., Chun, I., Yang, N., et al. (2023) · doi:10.1158/2159-8290.c.6549622.v1
Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2023) · doi:10.1158/2159-8290.c.6549389.v1
Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2023) · doi:10.1158/2159-8290.22540475.v1
CAR T in Childhood Acute Lymphoblastic Leukemia
Calkoen, F., & Buechner, J. (2024) · Pediatric oncology · doi:10.1007/978-3-031-71180-0_14
Introducing immunology: Types of immunity, immune responses, deficiencies, and disorders
Rahman, Z. N., Shehjar, F., & Mahajan, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18776-6.00001-3 · Cited by 1
Characterizing Nucleic Acid‐, Gene‐, and Cell‐Based Therapeutics with Sequencing Technologies
Bennett, H. M., Byrne, A., Stephenson, W., & Modrusan, Z. D. (2025) · Wiley eBooks · doi:10.1002/9781394236145.ch15
Recent advances of CRISPR screen in cancer immunology
Li, M., Li, W., Guo, H., & Hou, Y. (2025) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/csb-2025-5052
Genomic correlates of clinical CAR T cell activity
Leick, M. B., Sun, B., Birocchi, F., Gallagher, K., Bratt, A., Han, S., Martin, G. A., Silva, H. J., Larson, R. C., Chinsky, T. M., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.aef4134 · Cited by 2
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?
Li, A. M., & Maude, S. L. (2025) · Hematology · doi:10.1182/hematology.2025000735
Zhang, H., Qin, G., Zhang, C., Yang, H., Liu, J., Hu, H., Wu, P., liu, S., Yang, L., Chen, X., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14843083
Jiang, C., Hao, D., Jain, P., Li, Y., Cai, Q., Yao, Y., Nie, L., Liu, Y., Jin, J., Wang, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21213509
Additional file 2 of The journey of CAR-T therapy in hematological malignancies
Lu, J., & Jiang, G. (2022) · Figshare · doi:10.6084/m9.figshare.21303550
Additional file 1 of The journey of CAR-T therapy in hematological malignancies
Lu, J., & Jiang, G. (2022) · Figshare · doi:10.6084/m9.figshare.21303547
Zhang, H., Qin, G., Zhang, C., Yang, H., Liu, J., Hu, H., Wu, P., liu, S., Yang, L., Chen, X., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14843080
Integrated Chronic In Vivo and In Vitro Screens Uncover NFIL3 as a Driver of T-cell Dysfunction
Jain, N., Shi, Y., May, C., Mitra, S., Bucher, P., Dobrin, A., Zhao, Z., Hanina, S., Rajasekhar, V. K., Yao, Y., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1524 · Cited by 1
Shin, H.-S., Kwon, S.-G., Lee, H., & Lee, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.06.716844
Aboelella, N. S., Park, R., Tang, E., Asby, N. W., Ho, J. D., Pan, T., Wang, S. Y., Xie, L., Kline, J. P., Riedell, P. A., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02655-y · Cited by 2
“36 To test if TRAIL also played a signi fi cant role in venetoclax-treated CART-mediated killing, we performed neutralization experiments and found that antibody-mediated inhibition of TRAIL dose-dependently decreased venetoclax-and vehicle-treated CART ef fi cacy (Supplementary Fig.”
Challenges and advances in CAR-T cell therapy for B-ALL
Zha, C., & Wang, Y. (2026) · Biomarker Research · doi:10.1186/s40364-026-00933-z
“In B-ALL, the knockout of death receptor pathway genes [128, 129], CD58 (impairing immune synapse formation) [130], or the pro-apoptotic protein NOXA [131] leads to resistance.”
Li, P., Xue, X., & Zhang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1861111
“Marco Ruella and colleagues reported that impaired death receptor signaling pathways and elevated expression of antiapoptotic molecules reduce tumor cell sensitivity to CAR-T cell-induced killing (57).”
Metabolic feature profiling and metabolic vulnerability in acute lymphoblastic leukemia
Liang, X., Cai, Z., Tang, B., Huang, Z., Luo, B., Lin, B., Yang, Y., Jin, Z., Li, X., Xu, X., et al. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70134 · Cited by 1
Garcia, C., Lyons, K., Contreras, J. G., Liu, T., Donnelly, A. J., Novak, A. J., Argabright, A., Anderson, C. C., Grier, A. L., Smith, S., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03030-0
“We saw the enrichment of NALM-6 clones carrying either FADD [25] or CD19 [6] sgRNAs following CD19-directed CAR-T treatment (Supplementary Fig.”
Canty, J., Marsters, S. A., Lawrence, D., Lee, S., Koeppen, H., & Ashkenazi, A. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01798-3
Carriero, L., Re, L. D., Guardalupi, F., Giancola, R., Colasante, F., Corradi, G., Troiano, F., Michetti, N., Ricciuti, G., Schiattone, L., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02971-5
“Several mechanisms have been proposed to account for the failure of CAR-T cell therapy, including T cell exhaustion and apoptosis [4], antigen loss [5] and resistance of cancer cells to apoptosis [6].”
Ollame-Omvane, E., Khemis, L. B., Cordeiro, P., Fuchs, C., Richard-St-Hilaire, A., Béland, K., Haddad, É., Sinnett, D., Herblot, S., & Duval, M. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04502-z
Fan, J., Kutsch, N., Heger, J., Gödel, P., Heger, E., Gruell, H., Linde, P., Ferdinandus, S., Rosenbrock, J., Dapper, H., et al. (2026) · Acta Oncologica · doi:10.2340/1651-226x.2026.46287
“In B-cell ALL and DLBCL models, low-dose irradiation improved tumor control through activation of the death receptor pathway, a key regulator of CAR T-cell resistance [20, 22].”
Tumor cell–intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer
Fröse, J., Chen, E., Whittaker, C. A., Leclerc, P., Doherty, S., Langenbucher, A., Shao, J., Hellinger, R. D., Goulet, D. R., Tammela, T., et al. (2026) · Science Advances · doi:10.1126/sciadv.aeh8973 · Cited by 1
Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death
Levchuk, K., Petukhov, A., Tursymbek, S., Seitkamal, K., Bertleuova, A., Bulanin, D., & Barlev, N. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1963794
“Tumor-speci fi c defects in apoptotic or necroptotic pathways may further distort the action of in fl ammatory cytokines, protecting cancer cells from effective cell death despite the continuous immune pressure (24 – 26, 29, 31, 33).”
InfluentialWang, S., Liu, W., Wang, Y., Xu, Y., 邢海燕, 唐克晶, Tian, Z., Rao, Q., Qiu, S., Wei, H., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72395
Metadata
- Authors
- Singh, N., Lee, Y. G., Shestova, O., Ravikumar, P., Hayer, K. E., Hong, S. J., Lu, X. M., Pajarillo, R., Agarwal, S., Kuramitsu, S., Orlando, E. J., Mueller, K. T., Good, C. R., Berger, S. L., Shalem, O., Weitzman, M. D., Frey, N. V., Maude, S. L., Grupp, S. A., June, C. H., Gill, S., & Ruella, M.
- Affiliations
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Novartis (Switzerland) (CH)
- 5Novartis Institutes for Biomedical Research, East Hanover, New Jersey.
- Corresponding author
- Singh, Nathan
- Gill, Saar
- Ruella, Marco
- ORCID
- Singh, Nathan
- Lee, Yong Gu
- Ravikumar, Pranali
- Hayer, Katharina E.
- Hong, Seok Jae
- Lu, Xueqing Maggie
- Pajarillo, Raymone
- Agarwal, Sangya
- Kuramitsu, Shunichiro
- Orlando, Elena J.
- Mueller, Karen Thudium
- Good, Charly R.
- Berger, Shelley L.
- Shalem, Ophir
- Weitzman, Matthew D.
- Frey, Noelle V.
- Maude, Shannon L.
- Grupp, Stephan A.
- June, Carl H.
- Gill, Saar
- Ruella, Marco
- Venue
- Cancer Discovery
- Published
- 2020-04-01
- Volume
- 10
- Issue
- 4
- Pages
- 552-567
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3003403042
- Cited by
- 295
- References
- 49
- Citations by year
- 2026: 28 · 2025: 40 · 2024: 35 · 2023: 55 · 2022: 67 · 2021: 51 · 2020: 18
- FWCI
- 17.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Society of Immunotherapy for Cancer Holbrook Kohrt Immunotherapy Translational Fellowship
- Breakthrough Bike Challenge Buz Cooper Scholarship
- NCI (K08CA194256, 1K99CA212302, R00CA212302, 1P01CA214278, R01CA226983)
- American Society of Hematology Scholar Award
- Mark Foundation ASPIRE award
- University of Pennsylvania-Novartis Alliance
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- acute lymphoblastic leukemia, CAR T-cell therapy, CD19, chimeric antigen receptor, death receptor signaling, T cell cytotoxicity, CAR T-cell dysfunction, loss-of-function screen, B-cell malignancies, T cell fitness
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Signal Transduction, Receptors, Death Domain, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.